No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The S&P 500 gained 0.5% on Thursday, Jan. 23, reaching a record close as President Donald Trump pressed for lower oil prices ...

This stock can be held in an Investment ISA and an Investment Account ...